Key result
Transfemoral Trilogy TAVR achieves 98% technical success in symptomatic aortic regurgitation.
Why the study?
Despite being designed for symptomatic aortic regurgitation, data evaluating the JenaValve Trilogy Transcatheter Heart Valve System from large cohorts remained limited.
Cohort (n=363)
Yes
In a real-world multicenter cohort, TAVR with the dedicated JenaValve Trilogy device for symptomatic native aortic regurgitation demonstrated high technical success (98%) and low early mortality, supporting its potential role in patients unsuitable for surgery.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“We have clearly demonstrated that it's technically possible to treat these patients with off-label use of the commercially available devices designed for aortic stenosis,... but looking at these retrospective analyses, the complication rate with dedicated devices is much lower and it appears to be safer, albeit with the limitations that they're likely to be different patient populations. But the differences are really marked.”
“Individuals ineligible or at high risk for SAVR were previously without treatment options, and our results give confidence to TAVI as a lifesaving procedure for AR patients”
“If the numbers are replicated with a larger sample size, this is for sure, in my opinion, going to be a really important device in treating patients with aortic regurgitation.”
Real-world data support Trilogy TAVR feasibility in AR; leaves open need for RCTs on durability and outcomes.
BACKGROUND: The JenaValve Trilogy Transcatheter Heart Valve System (Trilogy) is a CE-marked transcatheter aortic valve replacement device designed for the treatment of symptomatic aortic regurgitation. Despite its unique indication, data from large cohorts remain limited. This study aimed to evaluate procedural characteristics and clinical outcomes in all-comers patients with symptomatic aortic regurgitation undergoing transfemoral transcatheter aortic valve replacement with the Trilogy valve. METHODS: This multicenter retrospective analysis included patients with symptomatic aortic regurgitation who underwent Trilogy implantation between June 2021 and June 2025 at 8 European centers. Baseline, procedural, and follow-up data were collected according to local protocols, and outcomes were defined per VARC-3 (Valve Academic Research Consortium-3). RESULTS: A total of 363 patients (median age, 81 years [interquartile range, 75-84]; 45% female patients; median European System for Cardiac Operative Risk Evaluation II, 3.4%; median left ventricular ejection fraction, 50%) were included. Transfemoral access was used in 359 (99%), and technical success was achieved in 98%. Valve embolization occurred in 5 patients: 2 managed with a second valve, 2 surgically, and 1 required valve-in-valve reintervention. Two additional technical failures involved hemodynamic instability and a vascular complication. At discharge, 86% had none or trace leakage, and the mean transvalvular gradient was 4 mm Hg. Permanent pacemaker implantation was required in 22%. In-hospital mortality was 0.3%. At 30 days, functional status had improved markedly, with 88% of patients in New York Heart Association class I or II. Kaplan-Meier estimated all-cause mortality at 6 months, 1, 2, and 3 years was 4.1%, 7.0%, 15.8%, and 25.9%, respectively, among patients with available follow-up. CONCLUSIONS: In this large analysis, transfemoral transcatheter aortic valve replacement with the Trilogy valve demonstrated high procedural success and favorable hemodynamic valve performance. These findings are encouraging and suggest a potential role for the Trilogy valve in patients with symptomatic aortic regurgitation who are unsuitable for surgery.
No takes yet. Share an insight, caveat, or question.
Wienemann et al. (2026) conducted a cohort in symptomatic aortic regurgitation (n=363). Trilogy valve was evaluated on Technical success. Transfemoral TAVR with the Trilogy valve achieved a 98% technical success rate and 0.3% in-hospital mortality in patients with symptomatic aortic regurgitation.
Synapse has enriched 10 related papers. Consider them for comparative context: